Biofoundries: which startup is ahead? Last updated: 31 July 2026 In our synthetic biology market deck , you will find everything you need to understand the market SUMMARY Asimov is ahead overall in the private biofoundry race, with Arzeda close behind and Culture Biosciences holding the strongest specialist position. The market is not converging around one universal biofoundry. Therapeutic cell engineering, industrial protein commercialization, bioprocess development, cloud protein testing and autonomous laboratory infrastructure are becoming separate businesses with different leaders. Asimov's lead comes from integration rather than one headline technology. Its cells, genetic parts, software, laboratory workflows and manufacturing partners sit around a customer program that can eventually reach the clinic, creating unusually high switching costs. Arzeda has the strongest commercial proof. ViaLeaf has moved beyond a technical demonstration into industrial production, measurable market adoption and global distribution through MANE, which is still rare among biofoundry-created products. Ginkgo remains the physical benchmark, but no longer the clean business-model benchmark. Its autonomous laboratories and large installations show what scale can look like, while falling revenue and continued cash use show how expensive that scale can become. Culture Biosciences occupies a less glamorous but important bottleneck. Many engineered cells fail during process development, so Culture's cloud bioreactors, software and installable hardware address the point where promising biology has to become reproducible manufacturing. Adaptyv Bio is the company most directly tied to the rise of AI-designed proteins. Transparent pricing, API ordering and short experimental cycles could make it the testing layer used by software agents that generate far more candidates than traditional laboratories can handle. Constructive Bio may own the deepest scientific moat, but it also carries the largest market-timing risk. Rewritten genomes and expanded genetic codes are hard to copy; the open question is how many customers need them badly enough to support a large platform business. Arzeda appears to have used its funding most efficiently, while Asimov has built the broadest high-value platform. Those are different achievements, and the gap between them explains why the overall ranking is close. For now, Asimov has the strongest combination of customers, clinical validation, manufacturing access and product expansion. Arzeda could overtake it with several more successful product launches, while Culture, Adaptyv and Constructive Bio each have a credible path to lead a narrower layer of the market. Which biofoundry startups are we actually comparing? We see six private biofoundry startups worth comparing today, with Ginkgo Bioworks kept as the public benchmark. A biofoundry should do more than sell software, manufacture somebody else's recipe or develop only its own biological products. For this comparison, a company must let outside customers use an integrated platform covering several stages of biological engineering, such as designing molecules, building organisms, running experiments, analyzing results or preparing a process for manufacturing. That definition gives us Asimov, Arzeda, Culture Biosciences, Constructive Bio, Adaptyv Bio and Triplebar. They remain very different businesses, but each gives customers access to biological engineering capabilities that would otherwise require a specialized laboratory, automation equipment and an experienced scientific team. We keep Ginkgo Bioworks in the analysis because it remains the largest commercial biofoundry benchmark. Ginkgo has been publicly traded since 2021, so calling it a startup would now be misleading. Leaving it out would also distort the comparison because every private biofoundry is still judged against the scale, ambition and difficulties of Ginkgo's model. We exclude Cradle because customers mainly use its software to design proteins before testing them elsewhere. Synthace sells laboratory software. Companies such as Generate Biomedicines and LabGenius operate sophisticated internal platforms, but they mainly use those platforms to develop their own drugs. Traditional contract research and manufacturing companies are also outside the scope when they simply carry out customer instructions. StrainX Bioworks recently emerged from stealth with 13millionforprecision−fermentationwork.Weareleavingitoutsidetherankingfornowbecauseitspublicmaterialsdonotyetshowabroadlyavailableexternalbiofoundryplatform.Privatefundingtotalsremainapproximate.Databasessometimescountgrants,smallextensionsandundisclosedroundsdifferently,soanarrowrangeismorehonestthanafalselyprecisenumber.CompanyWhatcustomersuseitforReportedcumulativefundingPlaceinthiscomparisonGinkgoBioworksAutomatedbiologicalexperiments,cellengineering,datagenerationandautonomouslaboratoryinstallationsAbout13 million for precision-fermentation work. We are leaving it outside the ranking for now because its public materials do not yet show a broadly available external biofoundry platform. Private funding totals remain approximate. Databases sometimes count grants, small extensions and undisclosed rounds differently, so a narrow range is more honest than a falsely precise number. Company What customers use it for Reported cumulative funding Place in this comparison Ginkgo Bioworks Automated biological experiments, cell engineering, data generation and autonomous laboratory installations About 1.3 billion in private capital before and around its listing Public benchmark Asimov Designing and manufacturing biologics, viral vectors and RNA therapeutics About 234millionCorecompetitorCultureBiosciencesCloud−connectedbioreactors,bioprocessservices,laboratoryhardwareandsoftwareAbout234 million Core competitor Culture Biosciences Cloud-connected bioreactors, bioprocess services, laboratory hardware and software About 101 million to 107millionCorecompetitorArzedaDesigningproteinsandturningthemintoindustrialproductsAbout107 million Core competitor Arzeda Designing proteins and turning them into industrial products About 95 million Core competitor Constructive Bio Building synthetic genomes and organisms that use an expanded genetic code 75millionCorecompetitorTriplebarScreeningverylargecellpopulationstoimprovebiologicsandproductionorganismsAbout75 million Core competitor Triplebar Screening very large cell populations to improve biologics and production organisms About 21 million Core competitor Adaptyv Bio Synthesizing and experimentally testing designed proteins through an automated cloud laboratory About 11millionCorecompetitorIsthereaclearbiofoundrystartupleaderrightnow?Asimoviscurrentlytheclearestprivatebiofoundryleader,althoughArzedaandCultureBiosciencesleadpartsofthemarketthatAsimovbarelyserves.Asimovhasbuiltthebroadestcredibleprivateplatformaroundtherapeuticmanufacturing.Morethan30therapeuticpartnershaveuseditsCHOEdgesystem,onebispecificantibodymadewiththeplatformhasenteredclinicaltesting,andcustomerscannowuseAsimovforantibodyoptimization,stablecell−linedevelopment,viral−vectorproductionandRNAdesign.Thecompanyhaskeptexpanding.ItsChrysalisgenome−integrationtoolproducedtopantibodyclonesabove12gramsperliterincustomercampaignsandmaintainedstableexpressionformorethan60cellgenerations.OtherrecentworkincludesanRNAoptimizationplatform,acompletedtrispecific−antibodycampaignwithMabylonandadevelopmentpartnershipwithMcGillUniversity′sGoodmanCancerInstitute.Arzedaisaheadonfinishedindustrialproducts.ItsViaLeafRebMsweetenerhasreachedcommercialproduction,gainedmeasurablemarketshareandsecuredaglobalproductionandcommercializationpartnerinMANE.CultureBiosciencesleadsthecloud−bioprocesslayer,wherecustomersneedtotestcellsinsidecontrolledbioreactorsandunderstandhowaprocessmightbehaveatlargerscale.Ginkgostilloperatesonanotherlevelphysically.ItsBostonautonomouslaboratory,cloud−labservicesand11 million Core competitor Is there a clear biofoundry startup leader right now? Asimov is currently the clearest private biofoundry leader, although Arzeda and Culture Biosciences lead parts of the market that Asimov barely serves. Asimov has built the broadest credible private platform around therapeutic manufacturing. More than 30 therapeutic partners have used its CHO Edge system, one bispecific antibody made with the platform has entered clinical testing, and customers can now use Asimov for antibody optimization, stable cell-line development, viral-vector production and RNA design. The company has kept expanding. Its Chrysalis genome-integration tool produced top antibody clones above 12 grams per liter in customer campaigns and maintained stable expression for more than 60 cell generations. Other recent work includes an RNA optimization platform, a completed trispecific-antibody campaign with Mabylon and a development partnership with McGill University's Goodman Cancer Institute. Arzeda is ahead on finished industrial products. Its ViaLeaf Reb M sweetener has reached commercial production, gained measurable market share and secured a global production and commercialization partner in MANE. Culture Biosciences leads the cloud-bioprocess layer, where customers need to test cells inside controlled bioreactors and understand how a process might behave at larger scale. Ginkgo still operates on another level physically. Its Boston autonomous laboratory, cloud-lab services and 47 million installation for Pacific Northwest National Laboratory are beyond the reach of the private companies. Its business performance is much less convincing. Continuing-operations revenue fell from 38millionto38 million to 19 million in the first quarter of 2026, while Ginkgo completed the sale of its biosecurity division and concentrated the company around autonomous laboratories. Ginkgo owns the largest infrastructure. The private field, though, is Asimov's to lose. If you want more recent data on this point, please see our latest synthetic biology market report . This market map, featured in our synthetic biology market deck , highlights top companies and startups in the synthetic biology market Which biofoundry has built the strongest scalable business? Arzeda has the clearest proof of a biofoundry-created product selling at industrial scale, while Asimov has built the stronger platform for high-value therapeutic manufacturing. ViaLeaf Reb M gives Arzeda something most biofoundries still lack: a product moving through a normal commercial supply chain. The sweetener entered the market in 2024, and Arzeda later reported more than 5% of the global Reb M market. Production capacity has passed 500 metric tons per year through external manufacturing partners. MANE has since expanded its relationship with Arzeda and taken responsibility for ViaLeaf production and global commercialization. MANE already sells flavors and ingredients to large food and beverage manufacturers, so Arzeda does not need to build an international sales and distribution organization alone. Arzeda's path from designed protein to market share is unusually strong evidence. The company had to make the protein work, develop an economical production process, complete regulatory work, produce consistent material and persuade food companies to use it. That is a real business, not just a platform demo. Asimov sells a higher-value but less transparent service. Pharmaceutical companies use its cells, genetic parts, software and development teams to improve the production of complex medicines. The company has named major partners including Amgen, Cytiva, LOTTE Biologics, AGC Biologics and BARDA, but it does not disclose revenue, contract values or customer retention. Asimov's scaling model depends on manufacturing partners rather than company-owned factories. Cytiva provides media and process-development services. LOTTE Biologics has demonstrated scale-up of CHO Edge. AGC Biologics can offer Asimov's lentiviral packaging system from its cell and gene therapy facility. Culture Biosciences has also built a real operating business. Customers have completed more than 20,000 bioreactor runs through its platform, and Culture now sells a combination of services, Console software and Stratyx laboratory equipment. The company has not disclosed enough installations or recurring software revenue to show that the newer model is scaling yet. Ginkgo can build larger automated laboratories than any private competitor. It delivered an 18-instrument anaerobic system to Pacific Northwest National Laboratory and then won a 47millioncontractfora97−instrumentinstallation.Thescalecomeswithheavyfinancialpressure,includingcontinuedcashburnwhilethecompanyrestructuresaroundautonomouslaboratories.Onvisibleindustrialoutput,Arzedahasthestrongercase.Fortherapeuticmanufacturing,Asimovdoes.Whichbiofoundrystartupisgaininggroundfastestnow?Asimovisgainingthemostgroundatmeaningfulscaletoday,whileAdaptyvBioisexpandingfastestfromamuchsmallerbase.Asimov′srecentactivityfollowsonecleardirection.Thecompanyissurroundingtherapeuticdeveloperswithmoretoolsateachstageofdevelopment,fromselectingamoleculetocreatingthecelllinethatwillmanufactureit.CHOEdgeRapidPoolsletscustomerstestmultipleantibodycandidatesinstablecellsbeforecommittingtoafinalmolecule.Mabylonusedthesystemtocomparetrispecificantibodiesandidentifyproblemsthatcouldhaveappearedmuchlaterindevelopment.ChrysalisthengivesAsimovaproprietarywaytoinserttherapeuticgenesintoproductioncells.RNAEdgeappliesasimilardesign−and−testlooptoRNAmedicines.Customeractivityhasmovedalongsidetheproductlaunches.ScorePharmabeganusingCHOEdgeforanimprovedcancerantibody.McGill′sGoodmanCancerInstituteselectedAsimovforcell−lineandprocess−developmentwork.AsimovalsocompletedacampaignwithMabylonandmadeitslentiviral−vectorsystemavailablethroughAGCBiologics.Adaptyvisgrowingfromafarsmallerstartingpoint,butitsrecentprogressdeservesattention.Thecompanysaysithastestedtensofthousandsofproteinsforpharmaceuticalcompanies,AIprotein−designstartups,academiclaboratoriesandindividualresearchers.CustomerscannoworderexperimentsthroughanAPI,receivecostestimatesautomaticallyandsendcandidatesdirectlyfromBenchling.ThatAPIcouldbecomeimportantasAImodelsgeneratemoreproteinsequencesthanhumanlaboratoriescantest.Amodelorsoftwareagentcansubmitcandidates,followtheexperimentandpullstructuredbindingorstabilitydatabackintothenextdesignround.Arzeda′smomentumismorecommercial.TheexpandedMANEagreementmovesViaLeaffurtherintonormalingredientproductionanddistribution.CultureispushingStratyxfromanearly−adopterproducttowardabroaderhardwarebusiness.TriplebarrecentlywonaBioMADE−backedprojecttoautomategenomicdesignforindustrialbiomanufacturing,althoughithasdisclosedfewernewcommercialcustomers.Asimovisthefastestmoveratrealscale.Adaptyvismovingfasterinpercentageterms,whichispromisingbutnotthesamething.Ifyouwantmorerecentdataonthispoint,pleaseseeourlatestsyntheticbiologymarketreport.Asthischartshows,andasfeaturedinoursyntheticbiologymarketdeck,searchinterestingeneeditinghasgrownsignificantlyWhichbiofoundryproductisreadyandworthpayingfortoday?Arzedahasthemostmaturefinishedproduct,whileAdaptyvBioofferstheclearestprice−to−speedpropositionandAsimovdeliversthemostvaluableresultsforcomplexdrugmanufacturing.AfoodmanufacturercanalreadypurchaseViaLeaf,formulateitintoaproductandobtainitthroughanestablishedingredientsupplier.Productionnowspansmultiplesites,andMANEprovidesindustrialmanufacturing,tasteformulation,customeraccessandcommercialdistribution.Asimov′sproductislessvisibletoordinaryconsumers,butithasreachedahighleveloftechnicalmaturity.CHOEdgeincludesproductioncells,alibraryofmorethan1,000characterizedgeneticparts,molecule−specificdesignsoftware,process−developmentsupportandregulatorydocumentation.AbispecificantibodyproducedwithCHOEdgereceivedFDAclearancetobeginclinicaltesting,andpatientsweresubsequentlydosedinaPhase1trial.CustomerscanalsomovefromAsimov′scell−lineworkintoprocessdevelopmentandGMPmanufacturingthroughpartnerssuchasCytiva,LOTTEBiologicsandAGCBiologics.Asimov′spricesremainprivate,butitsperformancecouldcreatelargesavingspersuccessfulprogram.CHOEdgehasroutinelyproducedclonesinthe8−to−11−gram−per−literrangeacrossdifferentbiologicformats.MorerecentcampaignsusingChrysalisproducedtopclonesabove12gramsperliter.InacollaborationwithAmgen,sequenceanalysisandtargetedchangesincreasedexpressionofalow−producingbispecificantibodyelevenfold.Thatkindofimprovementcandecidewhetherapromisingdrugispracticaltomanufacture.Adaptyvpublishespricesstartingataround47 million contract for a 97-instrument installation. The scale comes with heavy financial pressure, including continued cash burn while the company restructures around autonomous laboratories. On visible industrial output, Arzeda has the stronger case. For therapeutic manufacturing, Asimov does. Which biofoundry startup is gaining ground fastest now? Asimov is gaining the most ground at meaningful scale today, while Adaptyv Bio is expanding fastest from a much smaller base. Asimov's recent activity follows one clear direction. The company is surrounding therapeutic developers with more tools at each stage of development, from selecting a molecule to creating the cell line that will manufacture it. CHO Edge Rapid Pools lets customers test multiple antibody candidates in stable cells before committing to a final molecule. Mabylon used the system to compare trispecific antibodies and identify problems that could have appeared much later in development. Chrysalis then gives Asimov a proprietary way to insert therapeutic genes into production cells. RNA Edge applies a similar design-and-test loop to RNA medicines. Customer activity has moved alongside the product launches. Score Pharma began using CHO Edge for an improved cancer antibody. McGill's Goodman Cancer Institute selected Asimov for cell-line and process-development work. Asimov also completed a campaign with Mabylon and made its lentiviral-vector system available through AGC Biologics. Adaptyv is growing from a far smaller starting point, but its recent progress deserves attention. The company says it has tested tens of thousands of proteins for pharmaceutical companies, AI protein-design startups, academic laboratories and individual researchers. Customers can now order experiments through an API, receive cost estimates automatically and send candidates directly from Benchling. That API could become important as AI models generate more protein sequences than human laboratories can test. A model or software agent can submit candidates, follow the experiment and pull structured binding or stability data back into the next design round. Arzeda's momentum is more commercial. The expanded MANE agreement moves ViaLeaf further into normal ingredient production and distribution. Culture is pushing Stratyx from an early-adopter product toward a broader hardware business. Triplebar recently won a BioMADE-backed project to automate genomic design for industrial biomanufacturing, although it has disclosed fewer new commercial customers. Asimov is the fastest mover at real scale. Adaptyv is moving faster in percentage terms, which is promising but not the same thing. If you want more recent data on this point, please see our latest synthetic biology market report . As this chart shows, and as featured in our synthetic biology market deck , search interest in gene editing has grown significantly Which biofoundry product is ready and worth paying for today? Arzeda has the most mature finished product, while Adaptyv Bio offers the clearest price-to-speed proposition and Asimov delivers the most valuable results for complex drug manufacturing. A food manufacturer can already purchase ViaLeaf, formulate it into a product and obtain it through an established ingredient supplier. Production now spans multiple sites, and MANE provides industrial manufacturing, taste formulation, customer access and commercial distribution. Asimov's product is less visible to ordinary consumers, but it has reached a high level of technical maturity. CHO Edge includes production cells, a library of more than 1,000 characterized genetic parts, molecule-specific design software, process-development support and regulatory documentation. A bispecific antibody produced with CHO Edge received FDA clearance to begin clinical testing, and patients were subsequently dosed in a Phase 1 trial. Customers can also move from Asimov's cell-line work into process development and GMP manufacturing through partners such as Cytiva, LOTTE Biologics and AGC Biologics. Asimov's prices remain private, but its performance could create large savings per successful program. CHO Edge has routinely produced clones in the 8-to-11-gram-per-liter range across different biologic formats. More recent campaigns using Chrysalis produced top clones above 12 grams per liter. In a collaboration with Amgen, sequence analysis and targeted changes increased expression of a low-producing bispecific antibody elevenfold. That kind of improvement can decide whether a promising drug is practical to manufacture. Adaptyv publishes prices starting at around 149 per protein for a 96-protein binding screen, including two experimental replicates. The company says customers can move from submitted sequences to experimental data in less than three weeks. A protein-design team can therefore test a batch of AI-generated candidates without buying automation equipment, hiring a complete wet-lab group or negotiating a long custom research contract. The API provides a cost estimate before an order is placed. Culture Biosciences is also commercially available. Companies can ask Culture to run experiments remotely, install Stratyx bioreactors in their own laboratories and manage data through Console. Recent company-run comparisons found that Stratyx produced higher viable-cell density and antibody titer than another 250-milliliter bioreactor under the tested conditions. Constructive Bio remains earlier. The company can use synthetic genomes and recoded organisms to manufacture proteins containing amino acids that natural biology rarely uses, but commercial manufacturing remains limited. The practical answer depends on the job. Arzeda is furthest along as a finished product, Adaptyv is easiest to buy, and Asimov offers the strongest value for difficult therapeutic programs. Which biofoundry startup has won the strongest customers and contracts? Asimov has the strongest private-company customer portfolio, while Ginkgo holds the largest disclosed biofoundry contract. Asimov's customer list combines pharmaceutical developers, major equipment suppliers, contract manufacturers and the U.S. government. Amgen used the platform to improve expression of a difficult bispecific antibody. BARDA selected Asimov for work on manufacturing antibodies against dangerous viruses. Cytiva, LOTTE Biologics and AGC Biologics connect the technology to development and manufacturing facilities. Several smaller biotechnology companies have trusted Asimov with specific drug programs. Mabylon used Rapid Pools to choose among trispecific-antibody candidates. Score Pharma is using CHO Edge for an improved anti-HER2 antibody. Ottimo Pharma received a stable cell line for a PD1 and VEGFR2 antibody and transferred the work toward GMP manufacturing. These relationships go deeper than ordinary product trials. Choosing a production cell line affects process development, regulatory filings and future manufacturing, and changing it later can cost a drug developer considerable time and money. Ginkgo's $47 million Pacific Northwest National Laboratory project is the largest contract disclosed by any company in the comparison. Ginkgo also introduced ADME-One with Tangible Scientific and Inductive Bio, giving drug developers access to automated testing of how compounds may behave inside the body. The company said its Datapoints business worked with ten large pharmaceutical customers during its first full year. Arzeda has fewer disclosed customers, but its relationship with MANE carries unusual weight. MANE is now responsible for producing and commercializing ViaLeaf globally. Arzeda has effectively connected its protein-design platform to an existing multinational ingredient business. Culture Biosciences has worked with MilliporeSigma, Nektar, Cytovance Biologics and Modern Meadow. Public case studies show that customers use its reactors for real process-development decisions, although contract values and renewal rates remain hidden. Constructive Bio's agreement with the Ellison Institute included an upfront licensing payment, shared commercial rights and potential future royalties. That is a credible early deal, but its technology still has less customer validation than Asimov's platform. The clinical use of a molecule produced with CHO Edge tips this category toward Asimov. It is the clearest private winner on customer quality. This chart, featured in our synthetic biology market deck , illustrates yearly VC funding for synthetic biology startups Which biofoundry startup advantage will be hardest to copy? Asimov currently has the most useful defensible platform, although Constructive Bio owns the more unusual science. Asimov's advantage comes from several assets working together. It owns production cells, genetic components, design software, laboratory data, development workflows and a proprietary genome-integration system. Manufacturing partners have also adapted their processes around its technology. A competitor could build another genetic-design model or license a different CHO cell. Reproducing the complete system would require years of experiments connecting individual molecule designs with expression, stability, product quality and manufacturing performance. Chrysalis strengthens that position because Asimov owns the integration technology instead of depending entirely on an outside tool. Customers can license Chrysalis separately, use it through Asimov's broader platform or include it in a cell-line development